A

Altos Labs

Biotech startup advancing cellular rejuvenation therapies

Senior Manager/Manager - CRO and KOL Alliances

Contract
$79 - $123/hr
Senior
Bachelor's, Master's, PhD
San Diego, CA, USA
In PersonTravel required for CRO and institution site evaluations, audits, and oversight.
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • An advanced degree in life sciences (Master of Science, Doctor of Philosophy, Doctor of Veterinary Medicine, or equivalent) is preferred; a Bachelor of Science degree with significant relevant experience is considered.
  • At least 5 years of experience in biotechnology or pharmaceuticals, including at least 3 years directly managing contract research organizations, key opinion leader engagements, or external in vivo or translational studies.
  • A proven track record of scouting, onboarding, and managing top-tier key opinion leaders and establishing and running External Advisory Boards to guide translational, clinical, intellectual property, and regulatory strategy.
  • Deep practical knowledge of the end-to-end drug discovery and preclinical development process through lead optimization, candidate selection, and investigational new drug-enabling studies.
  • Strong understanding of in vivo pharmacology, disease models, and gene therapy modalities such as adeno-associated virus and lipid nanoparticles or related platforms.
  • Demonstrated experience translating scientific objectives into operational study plans and Statements of Work.
  • Strong proficiency in commercial and contractual terms, rate negotiations, and vendor governance frameworks.
  • Proven ability to manage multiple external partners and projects in parallel.
  • Excellent communication skills, with the ability to align diverse stakeholders and present clear updates to scientific and non-scientific audiences.
  • Ability to work in a fast-paced, highly cross-functional environment with evolving priorities.
Responsibilities
  • Lead identification, qualification, and ongoing management of the external research and development ecosystem.
  • Manage the full contract research organization engagement lifecycle from scientific scoping and competitive selection through work-schedule design, contract award, and ongoing data review against agreed quality and reporting standards.
  • Lead onboarding, governance, and strategic direction of key opinion leader networks across translational, clinical, and regulatory pathways.
  • Partner with scientific and program leads and internal functions to identify where outsourcing adds value, including large-animal models, disease-model optimization, and good laboratory practice or non-good laboratory practice studies.
  • Lead contract research organization evaluation and selection, including feasibility assessments, capability reviews, site qualification, and compliance reviews covering good clinical practice, good laboratory practice, animal welfare and Institutional Animal Care and Use Committee requirements, and intellectual property protection.
  • Design and execute vetting frameworks evaluating scientific rigor, technical capabilities, quality assurance standards, capacity, turnaround times, and regulatory compliance.
  • Translate scientific goals into structured, executable study plans and Statements of Work.
  • Align study objectives, endpoints, timelines, and decision points internally before engaging contract research organizations.
  • Ensure study designs include clear go/no-go criteria and data packages that inform subsequent program decisions.
  • Serve as the primary operational contact for contract research organizations, coordinating timelines, milestones, deliverables, operational bottlenecks, delays, and performance disputes.
  • Chair regular check-ins with contract research organizations, scientific leads, and internal functions to review progress, risks, and scope or timeline adjustments.
  • Track sample logistics, bioanalytical plans, and data transfers to support downstream analyses.
  • Assist Legal and Procurement with drafting, negotiating, and executing Master Services Agreements, Statements of Work, Consulting Agreements, and Material Transfer Agreements.
  • Assist with pricing and term negotiations and benchmark rates against industry standards to secure favorable, return-on-investment-driven agreements.
  • Lead the Request for Proposal process from end to end, including defining scope, gathering scientific requirements, and soliciting competitive bids from prospective vendors.
  • Build and manage annual contract research organization and key opinion leader spend forecasts with Finance and track actual strategic-portfolio spend.
  • Ensure contract research organization activities meet internal quality expectations and applicable regulatory and ethical standards.
  • Identify technical, operational, and timeline risks and drive mitigation plans with internal and external teams.
  • Support audit readiness and documentation requirements for key studies.
  • Identify, map, and qualify key opinion leaders, academic pioneers, and scientific experts based on publication impact and therapeutic expertise.
  • Coordinate vendor onboarding and execution of Consulting Agreements, Material Transfer Agreements, and advisor terms with Legal, Finance, and program leads.
  • Lead setup, operational cadence, and meeting governance for program-level External Advisory Boards and specialized expert panels.
  • Drive External Advisory Board and key opinion leader engagements to gather scientific input that shapes translational, clinical development, intellectual property, and regulatory strategies.
  • Synthesize advisory insights into actionable research and development takeaways and integrate recommendations into program decisions and milestones.
  • Work with biology, in vivo, pharmacology, technology operations, and program management teams to align priorities and resource allocation for outsourced work.
  • Provide updates on study status, risks, and decisions to project teams and leadership.
  • Create playbooks, templates, and best practices for external study management.
  • Capture learnings from contract research organization and key opinion leader engagements and use them to improve processes, vendor selection criteria, and study design practices.
  • Build and maintain a preferred vendor network and performance metrics for contract research organization and key opinion leader partners.
Desired Qualifications
  • An advanced degree in life sciences, specifically a Master of Science, Doctor of Philosophy, Doctor of Veterinary Medicine, or equivalent.

About the company

Altos Labs focuses on cell rejuvenation research to restore cellular health and resilience, with the aim of reversing diseases, injuries, and disabilities by programming cells to resist stressors that cause illness. It advances biotech R&D in cellular rejuvenation, producing treatments that can be commercialized for healthcare providers or patients and likely collaborates with research institutions and pharma partners. Unlike purely diagnostic firms, Altos Labs centers on developing breakthrough cellular therapies and regenerative strategies grounded in research, seeking to improve long-term health outcomes. Its goal is to translate cellular rejuvenation science into practical treatments that extend healthspan and reverse disease processes.

Company Size

501-1,000

Company Stage

Early VC

Total Funding

$3.3B

Headquarters

Redwood City, California

Founded

2021

Get referred to Altos Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 job postings show continued hiring across drug discovery, AI, and development.
  • Altos appointed Joan Mannick in 2025 to build clinical programs and product development.
  • The company still publicly tracks reverse-disease medicine, preserving a huge long-term upside.

What critics are saying

  • Altos has no registered human partial-reprogramming trials as of May 2026.
  • Recent reports cite departures of Steve Horvath and Peter Walter, signaling leadership churn.
  • If clinical translation stalls, Altos remains a very expensive academic lab with no product.

What makes Altos Labs unique

  • Altos Labs has $3 billion backing and recruits Nobel-caliber scientists.
  • Its 2026 team still spans Bay Area, San Diego, Cambridge, and Japan collaborations.
  • Joan Mannick's 2025 CMO role signals a rare push from discovery toward medicine.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
Red Hot Singapore I Pte. Ltd.
Sep 15th, 2026
AI models need more data about biology, and OpenAI is paying to create it.

AI models need more data about biology, and OpenAI is paying to create it. 1 hour ago 51 Last year, the clinical trial policy analyst Ruxandra Teslo posted an idea for super-charging medical AI systems: use data from failed biotech companies. By bidding at their bankruptcy proceedings, she proposed, it might be possible to obtain detailed regulatory filings, manufacturing strategies, and safety data - information usually kept hidden as valuable trade secrets. She called these documents "biotech's lost archive" and said they could be used to help train AIs that would act as powerful co-pilots in the often opaque drug approval process. Today, the OpenAI Foundation, the nonprofit parent of OpenAI, said it would fund her idea as part of a new effort it calls Data for Public Health, which aims to help artificial intelligence make big leaps in medicine by funding the creation of "high-quality scientific datasets." The basic idea is that AI isn't going to be capable of making important breakthroughs in curing disease unless researchers can feed the models much more information than they have so far. Explore AI Tools "Everyone is recognizing that data is the biggest bottleneck in successfully applying AI to biology," says Morgan Levine, a former vice president for computation at Altos Labs, a longevity company. In its initial round of data grants, the OpenAI Foundation announced it would give $40 million to a program to collect data about novel cancer vaccines at the University of North Carolina, Chapel Hill, and will also support OpenAdmet, a group that runs competitions in which researchers try to predict drug effects. Teslo's biotech archive idea received $500,000 and will be pursued by 1Day Sooner, an advocacy group representing clinical trial volunteers that she advises. "We expect many remaining breakthroughs in preventing and curing disease to come from pairing the intelligence of new models with more observations of the world - in other words, more data," the OpenAI Foundation said in a statement. OpenAI started as a nonprofit, but leader Sam Altman forked its personnel into a for-profit corporation that develops new models, launches products, and which is now planning an initial public offering of stock that could value it

VivaTech
Jul 30th, 2026
Can we slow aging? What VivaTech 2026 revealed about the future of Longevity.

Can VivaTech slow aging? What VivaTech 2026 revealed about the future of Longevity. Article by Collie Mall Copywriter @VivaTech Posted at: 07.30.2026 What if medicine could target aging itself? At VivaTech 2026, Dr. Joan Mannick of Altos Labs shared how breakthroughs in longevity research are bringing that possibility closer to reality. What if medicine could target aging itself, rather than simply treating the diseases that come with it? At VivaTech 2026, Dr. Joan Mannick, Chief Medical Officer and Head of Product Development at Altos Labs, explored that question during Longevity Unlocked: The Science Extending Human Healthspan. Her message was clear: the future of longevity isn't about living forever. It's about extending the years VivaTech spend healthy. "Most of us think longevity isn't about just living longer, it's about living healthier longer." She believes that future may arrive sooner than many expect. "In the next 10 years, we'll have our first drug approved targeting aging biology." Why scientists are targeting the biology of aging. For Mannick, aging is not simply the passage of time. It's the gradual loss of the body's ability to protect and repair itself. "What happens as we get older is we lose that buffer." Longevity research is focused on restoring that resilience, helping people stay healthier well into old age rather than treating one chronic disease after another. One of the most promising areas of research is cellular reprogramming. Mannick pointed to the Yamanaka factors, four proteins capable of resetting a cell's biological age, which are now being investigated in therapies designed to regenerate damaged tissue. Life Biosciences, for example, has launched clinical trials using this approach to restore vision in glaucoma patients. Artificial intelligence is accelerating that work by modelling virtual cells, identifying drug targets, and helping researchers understand one of biology's most complex systems. A review published in Nature concludes that targeting the biological mechanisms of aging could transform medicine by delaying multiple age-related diseases simultaneously, rather than treating each one independently. Despite the excitement surrounding the field, Mannick was equally clear about what works today. "Right now there's nothing that's been proven to extend lifespan or healthspan except exercise, reasonable diet, sleep." She also noted that she does not take longevity supplements herself, stressing the importance of evidence over hype. Longevity may be attracting unprecedented investment, but Mannick believes scientific rigor remains essential. She argued that progress will require patient capital, experienced teams, and a willingness to accept failure as part of discovery. "You can't be scared when you go into this field." That same philosophy shapes her confidence in regulation. Placebo-controlled clinical trials, she argued, remain the best way to understand whether new therapies truly work, while many supplements and peptides sold today have little evidence behind them. Why healthy aging matters. For Mannick, longevity is as much an economic challenge as a scientific one. As populations age, chronic diseases are placing increasing pressure on healthcare systems around the world. Alzheimer's disease, in particular, illustrates the scale of that challenge. "It's going to be over a trillion dollars in the next decade of costs." She believes therapies that target aging biology could transform healthcare in much the same way new medicines have reshaped the treatment of obesity and diabetes. "It will have an enormous impact like the GLP-1 ones. Enormous." Despite her optimism, Mannick remains careful not to overpromise. The field was inspired, she recalled, by Cynthia Kenyon's groundbreaking discovery that changing a single gene could double a worm's lifespan. Decades later, longevity science has matured into one of biotechnology's most ambitious frontiers, but its success will depend on rigorous evidence rather than bold claims. Her focus remains on delaying disease, not chasing immortality. "By targeting aging biology, we'll get one big chronic disease delayed that we couldn't delay before in a new way." Asked which disease she believed would be first, she smiled. "I'm going to take the fifth on that one." Want to explore the future of healthy aging? Watch the full replay of Longevity Unlocked: The Science Extending Human Healthspan, then join VivaTech at VivaTech 2027 as the world's leading scientists, entrepreneurs, and innovators continue exploring the breakthroughs shaping the future of health.

Longevity.Technology
Aug 5th, 2025
Is Altos Labs gearing up for clinical trials?

Longevity biotech giant Altos Labs has appointed Dr Joan Mannick as its Chief Medical Officer and head of product development, signaling a shift toward advancing clinical programs based on the company's cellular rejuvenation technology.

The Business Journals
May 21st, 2025
Jeff Bezos-backed, lifespan-focused Altos Labs buys small biotech with Stanford roots

Altos Labs, backed by $3 billion from Jeff Bezos and others, has snagged a small Peninsula company focused on one approach to stopping aging

The Spirits Business
Mar 27th, 2024
Altos is UK off-trade's leading 100% agave Tequila

In London, Altos recently launched its inaugural Margarita Masters competition for bartenders, with the hope of taking it nationwide in the future.